Figure 2.

Percentages of subjects with hSBA titres ≥1:4 before and after MenB-4C vaccination in infants and toddlers [52] (A) and adults (B) [54] across MenB indicator and diverse strains. In the infant/toddler study presented in panel A, infants received MenB-4C at 2, 4, 6, and 12 months of age; serum samples were taken at 2, 5, 7, 12, and 13 months of age. In the adult study presented in panel B, participants received 3 doses of MenB-4C, each spaced 1 month apart. Indicator strains 44/76-SL, NZ98/254, and 5/99 are intended to highlight responses against FHbp, PorA, and NadA, respectively [58]. Classification of the strains for each study in terms of the MenB-4C antigens is provided below the x-axis of each graph using data from the original studies, with – indicating low expression, +/− indicating medium expression, and +,++, and +++ indicating increasingly high expression. FHbp variants are indicated using the subfamily A/B classification scheme [22] as well as an alternative classification scheme involving 3 variant groups [37]. FHbp=factor H binding protein; hSBA=serum bactericidal antibody assay using human complement; MenB-4C= Bexsero^®, 4CMenB; NadA=Neisserial adhesin A; ND=not determined; NHBA=Neisserial Heparin Binding Antigen; PorA=porin A.